Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 1 1

Status

Unknown 1Suspended 1

Sponsor Class

OTHER 4INDUSTRY 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 199Breast Neoplasms 136Prostatic Neoplasms 72Neoplasms 62Neoplasm Metastasis 52Lung Neoplasms 45Stomach Neoplasms 27Parkinson Disease 4, Autosomal Dominant Lewy Body 22Squamous Cell Carcinoma of Head and Neck 17Ovarian Neoplasms 15Advanced Solid Tumors 14Recurrence 12Head and Neck Neoplasms 11Colorectal Neoplasms 11Carcinoma, Squamous Cell 11Urinary Bladder Neoplasms 10Melanoma 10Esophageal Neoplasms 10HER2-positive Breast Cancer 9Endometrial Neoplasms 9Carcinoma, Renal Cell 9Sarcoma 8Esophageal Squamous Cell Carcinoma 8Carcinoma, Transitional Cell 8Solid Tumor 7Prostatic Neoplasms, Castration-Resistant 7Pancreatic Neoplasms 7Carcinoma 7Triple Negative Breast Neoplasms 6Small Cell Lung Carcinoma 6

Interventions

Carboplatin 7aflutinib 5Pemetrexed 5osimertinib 4Gefitinib 4HM781-36B 3rezivertinib 2pembrolizumab 2Paclitaxel 2HMPL-013 2Docetaxel 2Cisplatin 2Albumin-Bound Paclitaxel 2tipifarnib 1sulindac sulfone 1spartalizumab 1icotinib 1aumolertinib 1apatinib 1Vinorelbine 1Taxes 1Gemcitabine 1Erlotinib Hydrochloride 1Clinical Trials, Phase I as Topic 1Cetuximab 1CP protocol 1Bortezomib 1BID protein, human 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
INDUSTRY × NSCLC × Docetaxel × Clear all
NCT05378763 2026-05-22

PINNACLE

Spectrum Pharmaceuticals, Inc

Phase 3 Suspended
268 enrolled
Thoracic

NSCLC

NCT04413227 2020-06-02

A Phase Ib Study With Pegylated Recombinant Human Endostatin in Advanced / Metastatic NSCLC or Other Solid Tumors

Jiangsu Simcere Pharmaceutical Co., Ltd.

Phase 1 Unknown
30 enrolled
Other solid neoplasmThoracic

NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡